Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACT therapy

- PMLiVE

France’s Innate Pharma eyes $100m Nasdaq IPO

Would help fund development of antibody-based immunotherapies

- PMLiVE

Breath test could predict response to immunotherapy

Study found device accurately predicted responses in lung cancer

- PMLiVE

Encouraging signs in biomarker R&D

The cancer immunotherapy firms ramping-up biomarker R&D

- PMLiVE

FDA starts speedy review of Merck’s Ebola vaccine

First company to file for approval in the US

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

Tecentriq approved in Europe for triple negative breast cancer

Roche can dominate in niche setting

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

GSK hires Merck KGaA exec to lead US pharma business

Martinez-Davis will help strengthen company’s oncology focus

- PMLiVE

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Proves continuing dominance in this indication

- PMLiVE

Trial backs role for Lynparza in second-line prostate cancer

Demonstrates potential significant benefit in treatment of disease

- PMLiVE

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links